Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)’s share price was up 3.5% on Monday . The company traded as high as $64.64 and last traded at $64.36, with a volume of 313,280 shares traded. The stock had previously closed at $62.18.

ALNY has been the subject of a number of research analyst reports. Jefferies Group reaffirmed a “buy” rating and set a $80.00 price objective (down from $119.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, June 8th. Cowen and Company reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Sunday, May 22nd. Chardan Capital reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, April 14th. Leerink Swann reduced their price objective on shares of Alnylam Pharmaceuticals from $120.00 to $107.00 and set an “outperform” rating for the company in a research report on Tuesday, May 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, May 4th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $117.82.

The stock’s market capitalization is $5.44 billion. The firm has a 50 day moving average of $62.18 and a 200-day moving average of $65.40.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Monday, May 2nd. The biopharmaceutical company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.05) by $0.16. During the same quarter in the previous year, the business posted ($0.62) EPS. The business earned $7.30 million during the quarter, compared to analyst estimates of $7.79 million. The company’s quarterly revenue was down 60.4% on a year-over-year basis. Equities analysts expect that Alnylam Pharmaceuticals Inc. will post ($4.94) EPS for the current fiscal year.

In other news, CEO John Maraganore sold 30,151 shares of the firm’s stock in a transaction on Wednesday, April 20th. The stock was sold at an average price of $67.46, for a total transaction of $2,033,986.46. Following the completion of the sale, the chief executive officer now directly owns 148,465 shares of the company’s stock, valued at approximately $10,015,448.90. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Several large investors have made changes to their positions in ALNY. Jennison Associates LLC raised its stake in shares of Alnylam Pharmaceuticals by 0.5% in the fourth quarter. Jennison Associates LLC now owns 1,489,541 shares of the biopharmaceutical company’s stock valued at $140,225,000 after buying an additional 7,296 shares in the last quarter. Advisors Asset Management Inc. raised its stake in shares of Alnylam Pharmaceuticals by 0.3% in the fourth quarter. Advisors Asset Management Inc. now owns 64,827 shares of the biopharmaceutical company’s stock valued at $6,103,000 after buying an additional 226 shares during the period. Mutual of America Capital Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 0.4% in the fourth quarter. Mutual of America Capital Management LLC now owns 21,637 shares of the biopharmaceutical company’s stock valued at $2,037,000 after buying an additional 87 shares during the period. Gulf International Bank UK Ltd raised its stake in shares of Alnylam Pharmaceuticals by 1.0% in the fourth quarter. Gulf International Bank UK Ltd now owns 23,100 shares of the biopharmaceutical company’s stock valued at $2,175,000 after buying an additional 220 shares during the period. Finally, Baillie Gifford & Co. raised its stake in shares of Alnylam Pharmaceuticals by 284.6% in the fourth quarter. Baillie Gifford & Co. now owns 2,727,734 shares of the biopharmaceutical company’s stock valued at $256,790,000 after buying an additional 2,018,484 shares during the period.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.